Search results

Skip to results

Type

Status

Last updated

Showing 1 result for danicopan with ravulizumab or eculizumab

  1. Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)

    Evidence-based recommendations on danicopan (Voydeya) with ravulizumab (Ultomiris) or eculizumab (Soliris) for paroxysmal nocturnal haemoglobinuria in adults with residual haemolytic anaemia.

    Technology appraisal guidance
    Published
    23 October 2024
    View recommendations

    Sections for TA1010